A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy.

Overall, our findings indicate that although single treatment using miR-CVB3 or CpGMel can efficiently delay tumor growth, combining oncolytic virus-based therapy can generate even stronger anti-tumor immunity, leading to a greater reduction in tumor size.